Genetic polymorphism of VEGF: Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients.

BACKGROUND Vascular endothelial growth factor (VEGF) plays a pivotal role in the peritoneal angiogenesis and hyperpermeability in patients on peritoneal dialysis. We hypothesis that VEGF genetic polymorphism may affect the longitudinal change of peritoneal transport and clinical outcome of peritoneal dialysis patients. METHODS We studied 135 consecutive new peritoneal dialysis patients. VEGF genetic polymorphism at -1154 and -2578 positions were determined by polymerase chain reaction (PCR) methodologies. Standard peritoneal test and dialysis adequacy and transport test (DATT) were performed at the initiation of peritoneal dialysis. After 12 months, DATT was repeated in 83 patients. In 35 patients, VEGF production in vivo was determined by its levels in serum and peritoneal dialysis effluent, and mRNA expression in peritoneal dialysis effluent. Patients were followed for 19.4 +/- 8.5 months for survival study. RESULTS There was no relation between VEGF genotype and baseline peritoneal transport group. The changes in 24-hour dialysate-to-plasma (D/P) creatinine after 12 months were 0.028 +/- 0.159, -0.013 +/- 0.137, and 0.141 +/- 0.231 for CC, CA, and AA genotype at -2578 position, respectively [one-way analysis of variance (ANOVA), P= 0.028]. The AA genotype had significantly higher increase in 24-hour D/P creatinine than the other genotypes. Similar results were found with the genotype at -1154 position, which had marked linkage disequilibrium with the genotype at -2578 position. Actuarial patient survival was 90.3% and 74.9% at 24 months for CC and CA/AA genotypes at -2578 position, respectively (P= 0.036). After correcting for confounding covariates, the adjusted hazard ratio of death was 3.04 (95% CI, 1.10 to 8.36) for the CA/AA group as compared to CC group. Although baseline serum VEGF level was higher in patients with CC genotype than those with CA/AA genotype at -2578 position (541.5 +/- 322.8 pg/mL vs. 298.8 +/- 209.4 pg/mL, P= 0.012), VEGF mRNA expression in peritoneal dialysis effluent was significantly lower in patients with CC genotype (1.82 +/- 2.77 vs 4.48 +/- 3.28, P= 0.021). VEGF protein level in peritoneal dialysis effluent was also marginally lower in patients with CC genotype, although the difference was not significant. Genotype at -1154 position was not associated with VEGF production in vivo or patient survival. CONCLUSION We conclude that in peritoneal dialysis patients, the AA genotype of VEGF promoter at -2578 position was associated with progressive increase in peritoneal transport. The CA/AA genotype at -2578 position was also associated with an excess mortality. Our finding also suggests that systemic and local peritoneal VEGF production may be differentially regulated.

[1]  H. Moore,et al.  Peritoneal Equilibration Test , 1987 .

[2]  K. Chow,et al.  Effects of an Angiotensin-Converting Enzyme Inhibitor on Residual Renal Function in Patients Receiving Peritoneal Dialysis , 2003, Annals of Internal Medicine.

[3]  T. Stompór,et al.  Selected Growth Factors in Peritoneal Dialysis: Their Relationship to Markers of Inflammation, Dialysis Adequacy, Residual Renal Function, and Peritoneal Membrane Transport , 2002, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[4]  P. Stenvinkel,et al.  Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  K. Syrigos,et al.  Circulating VEGF Levels in the Serum of Gastric Cancer Patients: Correlation With Pathological Variables, Patient Survival, and Tumor Surgery , 2002, Annals of surgery.

[6]  K. Chow,et al.  Dialysis adequacy and transport test for characterization of peritoneal transport type in Chinese peritoneal dialysis patients receiving three daily exchanges. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  F. Akçiçek,et al.  By Reducing Production of Vascular Endothelial Growth Factor Octreotide Improves the Peritoneal Vascular Alterations Induced by Hypertonic Peritoneal Dialysis Solution , 2002, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[8]  Ikuo Inoue,et al.  A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. , 2002, Diabetes.

[9]  H. Ha,et al.  Effects of Peritoneal Dialysis Solutions on the Secretion of Growth Factors and Extracellular Matrix Proteins by Human Peritoneal Mesothelial Cells , 2002, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[10]  C. Cohen,et al.  Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. , 2002, Kidney international.

[11]  H. Nielsen,et al.  Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma , 2002, British Journal of Cancer.

[12]  P. Harden,et al.  Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. , 2002, Journal of the American Society of Nephrology : JASN.

[13]  I. Jo,et al.  High Glucose Dialysis Solutions Increase Synthesis of Vascular Endothelial Growth Factors by Peritoneal Vascular Endothelial Cells , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[14]  M. Kolb,et al.  A Chronic Inflammatory Infusion Model of Peritoneal Dialysis in Rats , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[15]  R. Tilton,et al.  Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. , 2001, Journal of the American Society of Nephrology : JASN.

[16]  S. Davies,et al.  Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. , 2001, Journal of the American Society of Nephrology : JASN.

[17]  S. Fan,et al.  Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Li,et al.  Peritoneal transport status correlates with morbidity but not longitudinal change of nutritional status of continuous ambulatory peritoneal dialysis patients: a 2-year prospective study. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  R. Selgas,et al.  Spontaneous VEGF Production by Cultured Peritoneal Mesothelial Cells from Patients on Peritoneal Dialysis , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[20]  M. Bottomley,et al.  Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. , 2000, Cytokine.

[21]  P. Li,et al.  Importance of dialysis adequacy in mortality and morbidity of chinese CAPD patients. , 2000, Kidney international.

[22]  O. Devuyst,et al.  Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. , 2000, Journal of the American Society of Nephrology : JASN.

[23]  V. Pravica,et al.  Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. , 1999, Human immunology.

[24]  W. Smit,et al.  Growth factor VEGF and TGF-?1 in peritoneal dialysis , 1999 .

[25]  C. Szeto,et al.  Growth Factors in Continuous Ambulatory Peritoneal Dialysis Effluent , 1999, American Journal of Nephrology.

[26]  J. Isner,et al.  Therapeutic angiogenesis for heart failure , 1999, Nature Medicine.

[27]  S. Turner,et al.  ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β and TGF-β1 gene polymorphisms , 1999 .

[28]  J. Isner,et al.  Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. , 1998, The American journal of pathology.

[29]  D. Churchill,et al.  Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. , 1998, Journal of the American Society of Nephrology : JASN.

[30]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[31]  C. Cheung,et al.  Interference of creatinine measurement in CAPD fluid is dependent on glucose and creatinine concentrations. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  M. Rocco,et al.  24-Hour Dialysate Collection for Determination of Peritoneal Membrane Transport Characteristics: Longitudinal Follow-Up Data for the Dialysis Adequacy and Transport Test (Datt) , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[33]  D. Struijk,et al.  Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. , 1996, Journal of the American Society of Nephrology : JASN.

[34]  M. Rocchi,et al.  Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. , 1996, Circulation.

[35]  M. Rocco,et al.  Determination of peritoneal transport characteristics with 24-hour dialysate collections: dialysis adequacy and transport test. , 1994, Journal of the American Society of Nephrology : JASN.

[36]  D. Noe.  A body surface area nomogram based on the formula of Gehan and George. , 1991, Journal of pharmaceutical sciences.

[37]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[38]  J. Strackee,et al.  Simple assessment of the efficacy of peritoneal transport in continuous ambulatory peritoneal dialysis patients. , 1986, Blood purification.

[39]  G. Viberti.  Increased capillary permeability in diabetes mellitus and its relationship to microvascular angiopathy. , 1983, American Journal of Medicine.